Rapid Diagnosis of Parkinson’s Disease from Sebum using Paper Spray Ionisation Ion Mobility Mass Spectrometry

2020 ◽  
Author(s):  
Depanjan Sarkar ◽  
Drupad Trivedi ◽  
Eleanor Sinclair ◽  
Sze Hway Lim ◽  
Caitlin Walton-Doyle ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Ion Mobility ◽  
Neurodegenerative Disorder ◽  
Treatment Options ◽  
Ion Mobility Mass Spectrometry ◽  
Paper Spray ◽  
Molecular Features ◽  
Validation Set

Parkinson’s disease (PD) is the second most common neurodegenerative disorder for which identification of robust biomarkers to complement clinical PD diagnosis would accelerate treatment options and help to stratify disease progression. Here we demonstrate the use of paper spray ionisation coupled with ion mobility mass spectrometry (PSI IM-MS) to determine diagnostic molecular features of PD in sebum. PSI IM-MS was performed directly from skin swabs, collected from 34 people with PD and 30 matched control subjects as a training set and a further 91 samples from 5 different collection sites as a validation set. PSI IM-MS elucidates ~ 4200 features from each individual and we report two classes of lipids (namely phosphatidylcholine and cardiolipin) that differ significantly in the sebum of people with PD. Putative metabolite annotations are obtained using tandem mass spectrometry experiments combined with accurate mass measurements. Sample preparation and PSI IM-MS analysis and diagnosis can be performed ~5 minutes per sample offering a new route to for rapid and inexpensive confirmatory diagnosis of this disease.

Rapid Diagnosis of Parkinson’s Disease from Sebum using Paper Spray Ionisation Ion Mobility Mass Spectrometry

2020 ◽  
Author(s):  
Depanjan Sarkar ◽  
Drupad Trivedi ◽  
Eleanor Sinclair ◽  
Sze Hway Lim ◽  
Caitlin Walton-Doyle ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Ion Mobility ◽  
Neurodegenerative Disorder ◽  
Treatment Options ◽  
Ion Mobility Mass Spectrometry ◽  
Paper Spray ◽  
Molecular Features ◽  
Validation Set

Parkinson’s disease (PD) is the second most common neurodegenerative disorder for which identification of robust biomarkers to complement clinical PD diagnosis would accelerate treatment options and help to stratify disease progression. Here we demonstrate the use of paper spray ionisation coupled with ion mobility mass spectrometry (PSI IM-MS) to determine diagnostic molecular features of PD in sebum. PSI IM-MS was performed directly from skin swabs, collected from 34 people with PD and 30 matched control subjects as a training set and a further 91 samples from 5 different collection sites as a validation set. PSI IM-MS elucidates ~ 4200 features from each individual and we report two classes of lipids (namely phosphatidylcholine and cardiolipin) that differ significantly in the sebum of people with PD. Putative metabolite annotations are obtained using tandem mass spectrometry experiments combined with accurate mass measurements. Sample preparation and PSI IM-MS analysis and diagnosis can be performed ~5 minutes per sample offering a new route to for rapid and inexpensive confirmatory diagnosis of this disease.

scholarly journals Paper Spray Ionisation Ion Mobility Mass Spectrometry of Sebum Classifies Biomarker Classes for the Diagnosis of Parkinson’s Disease

2021 ◽  
Author(s):  
Depanjan Sarkar ◽  
Eleanor Sinclair ◽  
Sze Hway Lim ◽  
Caitlin Walton-Doyle ◽  
Kaneez Jafri ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Ion Mobility ◽  
Neurodegenerative Disorder ◽  
Collision Cross Section ◽  
Treatment Options ◽  
Ion Mobility Mass Spectrometry ◽  
Direct Infusion ◽  
Paper Spray

Parkinson’s disease (PD) is the second most common neurodegenerative disorder and identification of robust biomarkers to complement clinical diagnosis will accelerate treatment options. Here we demonstrate the use of direct infusion of sebum from skin swabs using paper spray ionisation coupled with ion mobility mass spectrometry (PS-IM-MS) to determine the regulation of molecular classes of lipids in sebum that are diagnostic of PD. A PS-IM-MS method for sebum samples that takes three minutes per swab was developed and optimised. The method was applied to skin swabs collected from 150 people and elucidates ~ 4200 features from each subject which were independently analysed. The data included high molecular weight lipids (>600 Da.) that differ significantly in the sebum of people with PD. Putative metabolite annotations of several lipid classes, predominantly triglycerides and larger acyl glycerides, were obtained using accurate mass, tandem mass spectrometry and collision cross section measurements.

Role of the community nurse in Parkinson's disease and lower urinary disorders

2021 ◽  
Vol 26 (5) ◽  
pp. 251-254
Author(s):  
Debbie Duncan
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorder ◽  
Treatment Options ◽  
Community Nurse ◽  
Bladder Training ◽  
Urinary Disorders ◽  
Incontinence Products ◽  
Lower Urinary

Parkinson's disease (PD) is an incurable and progressive neurodegenerative disorder. People with PD also have increased muscle weakness and the typical symptoms of tremor, stiffness, slowness, balance problems and/or gait disorders. Other symptoms may include an overactive bladder, urgency and nocturia which can often lead to incontinence. Treatment options vary are dependent on the cause of the incontinence and should focus on improving Quality of life with a multi-pronged diagnosis-specific approach that takes into consideration a patient's ability to comply with treatment. The article looks at the role of the community nurse in caring for patients with PD and lower urinary disorders. They have a key role in assessment of patients and supporting families with tailor made bladder training such as establish a regular toilet routine, education about pelvic floor exercises or supply of incontinence products.

scholarly journals Current treatment options for Parkinson’s disease and the existing status of nanotechnology

2020 ◽  
Vol 11 (2) ◽  
pp. 2410-2423
Author(s):  
Kannekanti Teja ◽  
Asha Spandana K M ◽  
Amit B Patil1 ◽  
Vishakante Gowda D ◽  
Narahari Rishitha
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Gene Therapy ◽  
Central Nervous System ◽  
Parkinson's Disease ◽  
Nervous System ◽  
Neurodegenerative Disorder ◽  
Treatment Options ◽  
Nano Particles ◽  
The Central Nervous System

Parkinson's disease (PD) is a neurodegenerative disorder associated with dopaminergic neuron degeneration and/or loss of neuronal activity. Current idiopathic PD treatments focus primarily on the use of pharmacological agents to improve PD patients ' motor symptoms. PD remains to be an incurable disease so far. Therefore, the development of new therapeutic approaches for PD therapy is of utmost significance. Several molecular and gene therapy methods have been established over the past 20 years to counteract or retard the development of PD. Severe side effects are found in many native therapies. Therefore, novel therapeutic strategies remain in demand for development. Nanomedicine seems to be a significant medical application in nanotechnology that demonstrates promising future in drug delivery to the central nervous system. BBB stands throughout the central nervous system as a gateway to drug targeting. Drug delivery, based on nano-particles that always avoids Blood-Brain Barrier protection, Different potential therapies based on nanoparticles and nanosystems are explored various benefits. The scope of this review is to provide an overview of this field of PD-related therapies and significant breakthroughs. To do so, this review will begin by concentrating on PD characterization, pathophysiology, etiology and present therapy choices that subsequently cover molecular, gene therapy, and nanotechnology formulations that are currently being studied in animal PD models or lately tested in clinical trials.

scholarly journals Current Approaches and Tools Used in Drug Development against Parkinson’s Disease

Biomolecules ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 897
Author(s):  
Oliwia Koszła ◽  
Piotr Stępnicki ◽  
Agata Zięba ◽  
Angelika Grudzińska ◽  
Dariusz Matosiuk ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorder ◽  
Treatment Options ◽  
New Drugs ◽  
Computer Assisted ◽  
Therapeutic Effects ◽  
New Compounds ◽  
The Brain ◽  
Selection Of

Parkinson’s disease is a progressive neurodegenerative disorder characterized by the death of nerve cells in the substantia nigra of the brain. The treatment options for this disease are very limited as currently the treatment is mainly symptomatic, and the available drugs are not able to completely stop the progression of the disease but only to slow it down. There is still a need to search for new compounds with the most optimal pharmacological profile that would stop the rapidly progressing disease. An increasing understanding of Parkinson’s pathogenesis and the discovery of new molecular targets pave the way to develop new therapeutic agents. The use and selection of appropriate cell and animal models that better reflect pathogenic changes in the brain is a key aspect of the research. In addition, computer-assisted drug design methods are a promising approach to developing effective compounds with potential therapeutic effects. In light of the above, in this review, we present current approaches for developing new drugs for Parkinson’s disease.

scholarly journals Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

Biomolecules ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 612
Author(s):  
Frank C. Church
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorder ◽  
Treatment Options ◽  
Neuronal Cell ◽  
Cell Loss ◽  
Management Program ◽  
Additional Treatment ◽  
Substantia Nigra Pars Compacta ◽  
Speech Pathology

Parkinson’s disease (PD) usually presents in older adults and typically has both motor and non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from dopaminergic neuronal cell loss in the mid-brain substantia nigra pars compacta region. Outlined here is an integrative medicine and health strategy that highlights five treatment options for people with Parkinson’s (PwP): rehabilitate, therapy, restorative, maintenance, and surgery. Rehabilitating begins following the diagnosis and throughout any additional treatment processes, especially vis-à-vis consulting with physical, occupational, and/or speech pathology therapist(s). Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine agonist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds. Restorative uses strenuous aerobic exercise programs that can be neuroprotective. Maintenance uses complementary and alternative medicine substances that potentially support and protect the brain microenvironment. Finally, surgery, including deep brain stimulation, is pursued when PwP fail to respond positively to other treatment options. There is currently no cure for PD. In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson’s disease.

Sign in / Sign up

Export Citation Format

Share Document